CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody™
therapeutic technology platform, today announced the appointment of
Amy C. Peterson, M.D., as executive vice president and chief
development officer. In this new role, Dr. Peterson will have
oversight of a multi-disciplinary team focused on advancing all
aspects of CytomX’s clinical development activities and driving
value creation and differentiated patient outcomes across the
CytomX portfolio.
“Amy brings to CytomX extensive clinical development and
leadership skills along with a track record of implementing
successful oncology clinical strategies through product
registration which will benefit us enormously as we continue to
advance our novel and differentiated portfolio of Probody
therapeutics,” said Sean McCarthy, D. Phil., president, chief
executive officer and chairman of CytomX. “We are thrilled to
welcome Amy and look forward to her contributions as we take CytomX
to the next level.”
Dr. Peterson brings 15 years of industry experience in oncology
drug development and has held multiple senior roles in leading
organizations. Most recently, Dr. Peterson was chief medical
officer of immuno-oncology at BeiGene, Ltd. where she created and
led a global oncology development organization with direct medical
oversight and accountability of 7 clinical assets in over thirty
global trials in all phases of development in solid tumor
indications. Prior to this, Dr. Peterson was vice president of
clinical development at Medivation where she was primarily
responsible for the development of enzalutamide (XTANDI®) and
talazoparib (TALZENNA®) in breast cancer. Previously, Dr. Peterson
served as associate group medical director at Genentech, where she
was responsible for the development of early stage molecules
targeting multiple major pathways in oncology. Prior to joining
Genentech, Dr. Peterson was an Instructor of Medicine in Oncology
at the University of Chicago, where she conducted translational
research in tumor immunology in conjunction with Dr. Thomas F.
Gajewski. Dr. Peterson received her M.D. from Thomas Jefferson
University and completed her residency in Internal Medicine at
Northwestern Memorial Hospital and Fellowship in Hematology and
Oncology at the University of Chicago. Dr. Peterson received her
B.A. degree from Wesleyan University.
“I am excited to be joining CytomX at this important time in the
company’s evolution as we seek to build further on the strong
technical and clinical foundation the company has laid for the
Probody therapeutic platform. My vision is to help drive the
organization to fully realize its potential as we strive to bring
transformative medicines to patients and their families,” said Dr.
Peterson.
CytomX also announced today two new additional management
appointments: Glenn Michelson, M.D., as vice president, clinical
development and Jason Braun, MBA, as vice president, commercial
strategy.
“I am delighted to welcome Glenn and Jason, two accomplished
oncology industry professionals, to the CytomX team at this
exciting time as we make progress in advancing our portfolio of
wholly-owned and partnered programs into later stages of clinical
development. Their extensive experience at other leading oncology
companies will be of great benefit to us,” said Amy Peterson, Chief
Development Officer.
Dr. Michelson brings over 20 years of hematology and oncology
drug development experience including extensive knowledge of
translational medicine and medical affairs having overseen and
managed numerous clinical programs from IND through Phase 3. Most
recently, Dr. Michelson was vice president of clinical development
at Portola Pharmaceuticals where he led the clinical development of
cerdulatinib. Prior to Portola, Dr. Michelson held the role of
chief medical officer and vice president of clinical development at
Plexxikon. Dr. Michelson received his M.D. from the University
of Louisville School of Medicine.
Mr. Braun brings 15 years of industry experience that
includes pipeline analysis, sales and marketing. Most recently, Mr.
Braun was vice president and head of commercial for Optera
Therapeutics, a privately held cell therapy company, where he
oversaw commercial strategy and product portfolio
analysis. Prior to Optera, Mr. Braun held leadership roles in
hematology and oncology marketing at Kite Pharma (now a subsidiary
of Gilead Sciences) where he led the U.S. marketing team during
preparation and launch of YESCARTA™, the first autologous CAR-T
therapy for adults with DLBCL, and at Pharmacyclics, where he led
the U.S. marketing team for IMBRUVICA®. Mr. Braun
received his Bachelor of Science degree in Chemical Engineering
from Lehigh University, an MBA from the Kellogg School of
Management at Northwestern University and a Master of Engineering
Management degree from Northwestern University.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused
biopharmaceutical company pioneering a novel class of
investigational antibody therapeutics based on its Probody™
therapeutic technology platform. Probody therapeutics are designed
to exploit unique conditions of the tumor microenvironment to more
effectively localize antibody binding and activity while minimizing
binding, and therefore activity in healthy tissues. CytomX and its
partners have four programs in the clinic. The Company’s
clinical stage pipeline includes cancer immunotherapies against
clinically validated targets, including a PD-L1-targeting Probody
therapeutic wholly owned by CytomX (CX-072) and a CTLA-4-targeting
Probody therapeutic partnered with Bristol Myers Squibb
(BMS-986249). The CytomX clinical stage pipeline also includes
first-in-class Probody drug conjugates against highly attractive
targets, including a CD166-targeting Probody drug conjugate wholly
owned by CytomX (CX-2009), and a CD71-targeting Probody drug
conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among
cancer targets that are considered to be inaccessible to
conventional antibody drug conjugates due to their presence on many
healthy tissues. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Amgen, Bristol-Myers
Squibb Company and ImmunoGen, Inc. For more information, visit
www.cytomx.com.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements, including those relating to
the potential benefits, safety and efficacy of CytomX’s or any of
its collaborative partners’ product candidates, administered
separately or in combination, the potential benefits or
applications of CytomX’s Probody platform technology and CytomX’s
ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing
clinical trials of CX-072 and CX-2009. Risks and uncertainties that
contribute to the uncertain nature of the forward-looking
statements include: the unproven nature of CytomX’s novel Probody
Platform technology; four of CytomX’s product candidates under its
Probody platform are in the initial stages of clinical development
and its other product candidates are currently in preclinical
development, and the process by which preclinical and clinical
development could potentially lead to an approved product is long
and subject to significant risks and uncertainties; the possibility
that the results of early clinical trials may not be predictive of
future results; the possibility that CytomX’s clinical trials will
not be successful; CytomX’s dependence on the success of CX-072,
CX-2009, CX-2029 and BMS 986249; CytomX’s reliance on third parties
for the manufacture of the company’s product candidates; and
possible regulatory developments in the United States and foreign
countries. Additional applicable risks and
uncertainties include those relating to our preclinical research
and development, clinical development, and other risks identified
under the heading "Risk Factors" included in CytomX’s Quarterly
Report on Form 10-Q filed with the SEC on August 7, 2019. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
PROBODY is a registered trademark of CytomX Therapeutics.
YESCARTA is a registered trademark of Gilead Sciences, Inc., or
its related companies.
IMBRUVICA is a registered trademark of Pharmacyclics LLC.
XTANDI and TALZENNA are registered trademarks of Pfizer,
Inc.
Contact:
Investors and Media:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/aaf29b5c-6419-4dc1-b2b6-5b62d72fd5b3
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2024 to May 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From May 2023 to May 2024